Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2017 08:00 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA

Data to highlight recent preclinical studies of SB 11285, a novel next-generation STING agonist HOPKINTON, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH),...
September 13, 2017 08:00 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank to Present at the Cantor Fitzgerald Global Healthcare Conference

HOPKINTON, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
August 28, 2017 08:30 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C.

HOPKINTON, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
July 31, 2017 16:15 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results

Reports multiple recent developments and milestones Plans to report top-line results from the second monotherapy dosing cohort of the ACHIEVE global Phase 2 clinical trial of SB 9200 in chronic HBV...
July 10, 2017 08:30 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®

HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
June 22, 2017 09:00 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Prices $37.5 Million Public Offering of Common Stock

HOPKINTON, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
June 21, 2017 16:00 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Announces Proposed Public Offering of Common Stock

HOPKINTON, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
June 07, 2017 07:00 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285

HOPKINTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) announced today that an abstract regarding its lead STING agonist candidate was published at the...
May 23, 2017 16:00 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)

SB 9200 Shows Favorable Safety Profile and Significant Antiviral Activity Against HBV DNA and HBsAg with Initial Low Dose Monotherapy of 25mg Conference Call Scheduled for Tomorrow, May 24th...
May 22, 2017 16:00 ET | Source: Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial

HOPKINTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...